141 related articles for article (PubMed ID: 22342821)
1. Targeting phosphatases as the next generation of disease modifying therapeutics for Parkinson's disease.
Braithwaite SP; Voronkov M; Stock JB; Mouradian MM
Neurochem Int; 2012 Nov; 61(6):899-906. PubMed ID: 22342821
[TBL] [Abstract][Full Text] [Related]
2. α-Synuclein phosphorylation as a therapeutic target in Parkinson's disease.
Braithwaite SP; Stock JB; Mouradian MM
Rev Neurosci; 2012 Mar; 23(2):191-8. PubMed ID: 22499677
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylation of LRRK2: from kinase to substrate.
Lobbestael E; Baekelandt V; Taymans JM
Biochem Soc Trans; 2012 Oct; 40(5):1102-10. PubMed ID: 22988873
[TBL] [Abstract][Full Text] [Related]
4. Leucine-rich repeat kinase 2 inhibitors: a review of recent patents (2011 - 2013).
Kethiri RR; Bakthavatchalam R
Expert Opin Ther Pat; 2014 Jul; 24(7):745-57. PubMed ID: 24918198
[TBL] [Abstract][Full Text] [Related]
5. Measurement of LRRK2 and Ser910/935 phosphorylated LRRK2 in peripheral blood mononuclear cells from idiopathic Parkinson's disease patients.
Dzamko N; Chua G; Ranola M; Rowe DB; Halliday GM
J Parkinsons Dis; 2013; 3(2):145-52. PubMed ID: 23938344
[TBL] [Abstract][Full Text] [Related]
6. Kinases as targets for Parkinson's disease: from genetics to therapy.
Vancraenenbroeck R; Lobbestael E; Maeyer MD; Baekelandt V; Taymans JM
CNS Neurol Disord Drug Targets; 2011 Sep; 10(6):724-40. PubMed ID: 21838679
[TBL] [Abstract][Full Text] [Related]
7. [Clinical molecular genetics for PARK8 (LRRK2)].
Tomiyama H; Hatano T; Hattori N
Brain Nerve; 2007 Aug; 59(8):839-50. PubMed ID: 17713120
[TBL] [Abstract][Full Text] [Related]
8. Can the increasing number of newly developed leucine-rich repeat kinase 2 inhibitors validate or invalidate a potential disease-modifying therapeutic approach for Parkinson's disease?
Taymans JM
Expert Opin Ther Pat; 2014 Jul; 24(7):727-30. PubMed ID: 24875782
[TBL] [Abstract][Full Text] [Related]
9. Lrrk2 phosphorylates alpha synuclein at serine 129: Parkinson disease implications.
Qing H; Wong W; McGeer EG; McGeer PL
Biochem Biophys Res Commun; 2009 Sep; 387(1):149-52. PubMed ID: 19576176
[TBL] [Abstract][Full Text] [Related]
10. Autosomal dominant Parkinson's disease and the route to new therapies.
Morris HR
Expert Rev Neurother; 2007 Jun; 7(6):649-56. PubMed ID: 17563248
[TBL] [Abstract][Full Text] [Related]
11. Novel LRRK2 GTP-binding inhibitors reduced degeneration in Parkinson's disease cell and mouse models.
Li T; Yang D; Zhong S; Thomas JM; Xue F; Liu J; Kong L; Voulalas P; Hassan HE; Park JS; MacKerell AD; Smith WW
Hum Mol Genet; 2014 Dec; 23(23):6212-22. PubMed ID: 24993787
[TBL] [Abstract][Full Text] [Related]
12. Leucine-rich repeat kinase 2 inhibitors: a patent review (2006 - 2011).
Deng X; Choi HG; Buhrlage SJ; Gray NS
Expert Opin Ther Pat; 2012 Dec; 22(12):1415-26. PubMed ID: 23126385
[TBL] [Abstract][Full Text] [Related]
13. The impact of reactive oxygen species and genetic mitochondrial mutations in Parkinson's disease.
Zuo L; Motherwell MS
Gene; 2013 Dec; 532(1):18-23. PubMed ID: 23954870
[TBL] [Abstract][Full Text] [Related]
14. [Pathogenesis of Parkinson's disease: implications from familial Parkinson's disease].
Iwatsubo T; Ito G; Takatori S; Hannno Y; Kuwahara T
Rinsho Shinkeigaku; 2005 Nov; 45(11):899-901. PubMed ID: 16447757
[TBL] [Abstract][Full Text] [Related]
15. Role of LRRK2 kinase activity in the pathogenesis of Parkinson's disease.
Greggio E
Biochem Soc Trans; 2012 Oct; 40(5):1058-62. PubMed ID: 22988865
[TBL] [Abstract][Full Text] [Related]
16. Update on the genetics of Parkinson's disease.
Gasser T
Mov Disord; 2007 Sep; 22 Suppl 17():S343-50. PubMed ID: 18175395
[TBL] [Abstract][Full Text] [Related]
17. Mechanistic insight into the dominant mode of the Parkinson's disease-associated G2019S LRRK2 mutation.
Luzón-Toro B; Rubio de la Torre E; Delgado A; Pérez-Tur J; Hilfiker S
Hum Mol Genet; 2007 Sep; 16(17):2031-9. PubMed ID: 17584768
[TBL] [Abstract][Full Text] [Related]
18. LRRK2 and neurodegeneration.
Santpere G; Ferrer I
Acta Neuropathol; 2009 Mar; 117(3):227-46. PubMed ID: 19142648
[TBL] [Abstract][Full Text] [Related]
19. Adenoviral-mediated expression of G2019S LRRK2 induces striatal pathology in a kinase-dependent manner in a rat model of Parkinson's disease.
Tsika E; Nguyen AP; Dusonchet J; Colin P; Schneider BL; Moore DJ
Neurobiol Dis; 2015 May; 77():49-61. PubMed ID: 25731749
[TBL] [Abstract][Full Text] [Related]
20. [Advance of the study on LRRK2 gene in Parkinson's disease].
Zhang Y; Chen S
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Dec; 25(6):657-9. PubMed ID: 19065525
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
